TMEM200B and non-small cell lung carcinoma: Studies utilizing liquid biopsy have shown a positive correlation between blood-TMB (bTMB) and tTMB, suggesting that bTMB could serve as a promising prognostic biomarker for NSCLC patients receiving immunotherapy [55,56].